Severe graft-versus-host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT). Bone marrow mesenchymal stem cells (BM-MSCs) display immunosuppressive activity and have been previously shown to improve the outcome of GvHD therapy. | Turkish Journal of Biology Turk J Biol (2016) 40: 493-500 © TÜBİTAK doi: Research Article Third-party Wharton’s jelly mesenchymal stem cells for treatment of steroid-resistant acute and chronic graft-versus-host disease: a report of 10 cases 1 1 2 Dariusz BORUCZKOWSKI , Dominika GŁADYSZ , Sławomir RUMIŃSKI , 1 1 1 3 Iwona CZAPLICKA-SZMAUS , Magdalena MURZYN , Artur OLKOWICZ , Krzysztof KAŁWAK , 3 4 5 6 Monika MIELCAREK , Katarzyna DRABKO , Jan STYCZYŃSKI , Mirosław MARKIEWICZ , 1,7, 8 1 Katarzyna PAWELEC *, Maciej BORUCZKOWSKI , Tomasz OŁDAK 1 Polish Stem Cell Bank, Warsaw, Poland 2 Warsaw Medical University, Poland 3 Department of Bone Marrow Transplantation, Pediatric Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland 4 Department of Pediatric Hematology and Oncology and Transplantology, Medical University of Lublin, Lublin, Poland 5 Department of Pediatric Hematology and Oncology, Collegium Medicum, UMK, Bydgoszcz, Poland 6 Medical University of Silesia, School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland 7 Department of Pediatric Hematology and Oncology, Medical University of Warsaw, Warsaw, Poland 8 Poznan University of Medical Sciences, Poznan, Poland Received: Accepted/Published Online: Final Version: Abstract: Severe graft-versus-host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT). Bone marrow mesenchymal stem cells (BM-MSCs) display immunosuppressive activity and have been previously shown to improve the outcome of GvHD therapy. We describe the use of umbilical cord mesenchymal stem cells (WJ-MSCs) expanded in serum-free medium for the treatment of acute GvHD (aGvHD) and chronic GvHD (cGvHD) in 10 patients. After 1 to 3 WJ-MSC infusions at a median dose of × 106 cells/kg recipient body weight, a complete or partial
